Sialic-Acid-Related Enzymes of B Cells and Monocytes as Novel Markers to Discriminate Improvement Categories and to Fulfill Two Remission Definitions in Rheumatoid Arthritis
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241612998 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Lieh-Bang Liou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Allergy and Immunology, New Taipei Municipal Tucheng Hospital, New Taipei City 236, Taiwan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Rheumatic Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol-Myers Squibb (Taiwan) Ltd, Chang Gung Medical Foundation, Bristol–Myers Squibb (Taiwan) Ltd..
Abstract (Originalsprache)
The enzymes α-2,6-sialyltransferase 1 (ST6Gal1), neuraminidase 1 (Neu1), α-2,3-sialyltransferase 1 (ST3Gal1), and neuraminidase 3 (Neu3) are known to affect immune cell function. However, it is not known whether the levels of these enzymes relate to remission definitions or differentiate American College of Rheumatology (ACR), European League Against Rheumatism (EULAR), and Simplified Disease Activity Index (SDAI) responses in patients with rheumatoid arthritis (RA). We measured the ST6Gal1, Neu1, ST3Gal1, and Neu3 levels of B cells and monocytes in RA patients and correlated the cells’ enzyme levels/ratios with the improvement in the ACR, EULAR and SDAI responses and with the two remission definitions. The difference in the B-cell Neu1 levels differed between the ACR 70% improvement and non-improvement groups (p = 0.043), between the EULAR good major response (improvement) and non-good response groups (p = 0.014), and also between the SDAI 50% or 70% improvement and non-improvement groups (p = 0.001 and 0.018, respectively). The same held true when the RA patients were classified by positive rheumatoid factor or the use of biologics. The B-cell Neu1 levels significantly indicated 2005 modified American Rheumatism Association and 2011 ACR/EULAR remission definitions (area under the curve (AUC) = 0.674 with p = 0.001, and AUC = 0.682 with p < 0.001, respectively) in contrast to the CRP and ESR (all AUCs < 0.420). We suggest that B-cell Neu1 is superior for discriminating ACR, EULAR, and SDAI improvement and is good for predicting two kinds of remission definitions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Allergy and Immunology, New Taipei Municipal Tucheng Hospital, New Taipei City 236, Taiwan.
- Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital at Linkou, Taoyuan 333, Taiwan.
- School of Medicine, Chang Gung University College of Medicine, Taoyuan 333, Taiwan.
ORCID-Profile: Lieh-Bang Liou, Ping-Han Tsai, Jenn-Haung Lai
Förderung
- Bristol-Myers Squibb (Taiwan) Ltd
- Chang Gung Medical Foundation
- Bristol–Myers Squibb (Taiwan) Ltd.
Zitieren
APA
Liou, L. B., Tsai, P. H., Fang, Y. F., Chen, Y. F., Chen, C. C., & Lai, J. H. (2023). Sialic-Acid-Related Enzymes of B Cells and Monocytes as Novel Markers to Discriminate Improvement Categories and to Fulfill Two Remission Definitions in Rheumatoid Arthritis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241612998
Vancouver
Liou LB, Tsai PH, Fang YF, Chen YF, Chen CC, Lai JH. Sialic-Acid-Related Enzymes of B Cells and Monocytes as Novel Markers to Discriminate Improvement Categories and to Fulfill Two Remission Definitions in Rheumatoid Arthritis. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241612998
BibTeX
@article{Liou2023,
author = {Liou, Lieh-Bang and Tsai, Ping-Han and Fang, Yao-Fan and Chen, Yen-Fu and Chen, Chih-Chieh and Lai, Jenn-Haung},
title = {Sialic-Acid-Related Enzymes of B Cells and Monocytes as Novel Markers to Discriminate Improvement Categories and to Fulfill Two Remission Definitions in Rheumatoid Arthritis},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241612998}
}
EUVIMED